Intravenous infusion of PAF affects ovulation, fertilization and preimplantation embryonic development in NZB x NZW F1 hybrid mice

Prostaglandins Other Lipid Mediat. 2008 Mar;85(3-4):125-33. doi: 10.1016/j.prostaglandins.2007.11.003. Epub 2007 Dec 4.

Abstract

Platelet Activating Factor (PAF) is a bioactive phospholipid, which exhibits a variety of biological activities and plays a significant role in all aspects of reproduction. In this work, a single intravenous injection of various concentrations of PAF shortly after Human Chorionic Gonadotropin (HCG) administration as well as 24 and 48 h before HCG administration was studied in NZB x NZW F1 hybrid mice. Optimum results were observed when PAF was injected just after the administration of HCG. In this protocol, the concentrations of PAF exhibited bell-shaped response to every stage of development. Any concentration of PAF between 5.5 x 10(-11) and 5.5 x 10(-15)g/g b.w., caused an improved ovulation rate, an increased fertilization rate, an increased rate of cell cycle and an enhanced hatching blastocyst rate (P<0.05 for all stages). Injection of lyso-PAF had no effect in any stage. Our data show that the effect of PAF on early stages of embryo development in vitro is dependent on its way of administration, on the concentrations used as well as on the time PAF is injected.

MeSH terms

  • Animals
  • Embryonic Development / drug effects*
  • Fertilization / drug effects*
  • Hybridization, Genetic
  • Infusions, Intravenous
  • Injections, Intravenous
  • Male
  • Mice
  • Mice, Inbred NZB
  • Ovulation / drug effects*
  • Platelet Activating Factor / administration & dosage
  • Platelet Activating Factor / analogs & derivatives
  • Platelet Activating Factor / pharmacology*
  • Superovulation

Substances

  • O-deacetyl platelet activating factor
  • Platelet Activating Factor